Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
批准号:
10674679
负责人:
DAVID M. HOLTZMAN
金额:
$62.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-01 至 2027-05-31
关键词:
Abeta clearanceAblationAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAmyloidAmyloid beta-ProteinAmyloid depositionAntibodiesAntibody TherapyApolipoprotein EAreaAstrocytesBlood VesselsBlood flowBrainCellsCerebral Amyloid AngiopathyCerebrovascular systemCollaborationsDepositionDevelopmentDiameterEdemaElderlyExcisionFibroblastsGene ExpressionGeneticGenotypeGoalsGrantHemorrhageHigh Density LipoproteinsHypercapniaImageImaging TechniquesImmuneImmune responseImmune systemImmunotherapyImpaired cognitionImpairmentIndividualInflammationIschemiaLeptomeningesLinkLiquid substanceLymphaticLymphatic functionMacrophageMeningealMeningeal lymphatic systemMethodsMicrogliaModelingMusMyeloid CellsNatural ImmunityNerve DegenerationOperative Surgical ProceduresPassive ImmunotherapyPathogenesisPathologicPathologyPericytesPlayPopulationPost-Translational Protein ProcessingReportingRiskRoleSenile PlaquesSmooth Muscle MyocytesVEGFC geneVascular DiseasesVascular Endothelial Growth Factor CVascular Smooth Muscleabeta depositionage relatedamyloid pathologyamyloidogenesisapolipoprotein E-4arteriolebrain parenchymacell typeexperimental studyimprovedmouse modelneuroimmunologyresponseside effectsingle-cell RNA sequencingtranscriptomevascular inflammation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract: Project 2 will investigate the interplay of APOE genotype, innate immunity, and meningeal
lymphatics on cerebral amyloid angiopathy (CAA) and the translational implications of modifying lymphatic
function on passive immunotherapy of CAA. CAA occurs in ~90% of individuals who develop Alzheimer’s
disease (AD) and can occur independently of AD. The pathological hallmarks of CAA are deposition of amyloid
composed in the majority of cases of amyloid-β (Aβ) along small arteriole vessel walls of the cerebral
vasculature and leptomeninges. CAA leads to loss of vascular smooth muscle cells, impaired vasoreactivity,
hemorrhages, and ischemia resulting in cognitive impairment and transient ischemic episodes. CAA is also
linked with edema and microhemorrhages that are common side effects observed with several anti-Aβ
antibodies known as amyloid-related imaging abnormalities (ARIA). The mechanisms underlying the
development of CAA are not well understood, but prior studies indicate that APOE genotype, perivascular fluid
flux, and innate immune cells can all influence CAA pathology. Like AD, APOE4 increases the risk of
developing CAA. Recently, we demonstrated that anti-apoE antibodies that target a form of apoE that co-
deposits with vascular amyloid reduced CAA and improved vascular function. In the brain parenchyma, apoE is
predominantly expressed by astrocytes and reactive microglia. Vascular-associated cells, such as perivascular
macrophages (PVMs), pericytes, and the recently described fibroblast-like vascular leptomeningeal cells
(VLMCs) are also reported to express apoE. ApoE produced by different cell types differ in their lipidation state
and post-translational modifications which could suggest a cell-specific role for apoE in CAA or subsequent
vascular dysfunction and inflammation. Recent studies by the Kipnis lab have shown important contributions of
the meningeal lymphatic system to Aβ deposition in parenchymal and leptomeningeal plaques. Impaired
clearance of Aβ from perivascular spaces may also contribute to the formation of CAA, although the role of the
meningeal immune system and the meningeal lymphatics in CAA formation and pathogenesis is unexplored.
We hypothesize that 1) apoE plays a multifaceted role in CAA formation by influencing perivascular Aβ
seeding and clearance in part via the meningeal lymphatic system and perivascular immune cells, 2)
the meningeal lymphatic system plays a key role in CAA formation; and 3) augmenting the meningeal
lymphatic system will increase the efficacy of anti-apoE immunotherapy reduction of CAA. We propose
these Aims: Aim 1: To determine effect of cell-type specific apoE expression on CAA and meningeal lymphatic
function. Aim 2: To determine the role of meningeal lymphatics on CAA pathology and associated
inflammation and vascular dysfunction. Aim 3: To determine the effect of lymphatic function on the efficacy of
anti-apoE antibody treatment on CAA and vascular dysfunction. Project 2 will collaborate extensively with all
Projects and Cores in this grant to accomplish these goals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10667466
-
项目类别:
-
资助金额:$53.02万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10407944
-
项目类别:
-
资助金额:$54.01万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administration Core
-
批准号:10622634
-
项目类别:
-
资助金额:$80.27万
-
财政年份:2020
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Alzheimer's Disease Research Center
-
批准号:10622633
-
项目类别:
-
资助金额:$307.63万
-
财政年份:2020
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Sleep and Circadian Rhythms in Alzheimer Disease: Potential bi-directional relationship with tau
-
批准号:9815588
-
项目类别:
-
资助金额:$369.43万
-
财政年份:2019
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Nervous System Development and Injury
-
批准号:9386458
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2016
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:8779836
-
项目类别:
-
资助金额:$59.46万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9060227
-
项目类别:
-
资助金额:$55.3万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9814735
-
项目类别:
-
资助金额:$376.01万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10006905
-
项目类别:
-
资助金额:$7.01万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8642679
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Dynamic Regulation of Amyloid-^ in the CNS
-
批准号:8331629
-
项目类别:
-
资助金额:$29.84万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8838268
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Effects of the Sleep/Wake Cycle on A-Beta, Tau and Spreading
-
批准号:10006907
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10246278
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10006909
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10246274
-
项目类别:
-
资助金额:$6.79万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8467068
-
项目类别:
-
资助金额:$110.69万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synaptic, Cellular Modulation of Abeta Metabolism
-
批准号:9764499
-
项目类别:
-
资助金额:$146.62万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8268731
-
项目类别:
-
资助金额:$116.73万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
海外基金